The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Morozova M.A.

Centre for Mental Health Research

Potanin S.S.

Centre for Mental Health Research

Rupchev G.E.

Centre for Mental Health Research

Burminsky D.S.

Centre for Mental Health Research

Lepilkina T.A.

Centre for Mental Health Research

Beniashvili A.G.

Centre for Mental Health Research

An effect of cholinesterase blockade on negative symptoms in schizophrenia

Authors:

Morozova M.A., Potanin S.S., Rupchev G.E., Burminsky D.S., Lepilkina T.A., Beniashvili A.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8): 37‑44

DOI: 10.17116/jnevro202112108137

Read: 2976 times

Download PDF (RU)
Contact the author
Table of contents

AN EFFECT OF CHOLINESTERASE BLOCKADE ON NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
AN EFFECT OF CHOLINESTERASE BLOCKADE ON NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

To cite this article:

Morozova MA, Potanin SS, Rupchev GE, Burminsky DS, Lepilkina TA, Beniashvili AG. An effect of cholinesterase blockade on negative symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):37‑44. (In Russ.)
https://doi.org/10.17116/jnevro202112108137

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Cognitive functions asse­ssment of elde­rly patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):46-50
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Asso­ciation of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Chro­nic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medi­cine. 2025;(2):5-16
Abstract:

Abstruct

OBJECTIVE

To assess the possibilities of influencing the severity of negative disorders in schizophrenic patients with cholinesterase blockade.

MATERIAL AND METHODS

The study included stable 26 patients (13 of them women), average age 40.4 (SD 11.7) with paranoid schizophrenia, episodic form according to ICD-10). All patients received antipsychotic therapy, which was not changed at least for 2 months. We used psychometric scales (Positive and Negative Syndrome Assessment Scale (PANSS), Global Functioning Scale (GAF), neurocognitive techniques (Brief Assessment of Cognition in Schizophrenia-BACS), projective psychological techniques (Rorschach test).

RESULTS AND CONCLUSION

The results of the study showed that augmentation of maintenance antipsychotic therapy with a cholinesterase blocker (ipidacrine at a dose of 20 mg per day) had positive impact on negative symptoms, decreasing the severity of emotional deficiency. The positive changes of cognitive impairment, measured with BACS, occurred regardless of changes in the severity of negative disorders, measured with PANSS. The Rorschach test showed an improvement in the conventional orientation of the patients’ thinking. No exacerbation of psychotic symptoms was registered.

Keywords:

schizophrenia
negative disorders
cognitive dysfunction
therapy
cholinesterase blockade

Authors:

Morozova M.A.

Centre for Mental Health Research

Potanin S.S.

Centre for Mental Health Research

Rupchev G.E.

Centre for Mental Health Research

Burminsky D.S.

Centre for Mental Health Research

Lepilkina T.A.

Centre for Mental Health Research

Beniashvili A.G.

Centre for Mental Health Research

Received:

17.02.2021

Accepted:

23.02.2021

Close metadata

References:

  1. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137(1-3):147-150.  https://doi.org/10.1016/j.schres.2012.01.015
  2. Hyman SE, Fenton WS. Medicine. What are the right targets for psychopharmacology? Science. 2003;299(5605):350-351.  https://doi.org/10.1126/science.1077141
  3. Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry J Assoc Eur Psychiatr. 2004;19(1):21-26.  https://doi.org/10.1016/j.eurpsy.2003.10.004
  4. Carpenter WT. Davis JM. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatry. 2012;17(12):1168-1173. https://doi.org/10.1038/mp.2012.121
  5. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry J Ment Sci. 2010;197(3):174-179.  https://doi.org/10.1192/bjp.bp.109.067710
  6. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138-149.  https://doi.org/10.4088/JCP.08m04666yel
  7. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G, Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol Oxf Engl. 2012;26(9):1185-1193. https://doi.org/10.1177/0269881112444941.
  8. Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis. 1996;184(5):295-301.  https://doi.org/10.1097/00005053-199605000-00005
  9. Amiri A, Noorbala A-A, Nejatisafa A-A, Ghoreishi A, Derakhshan M-K, Khodaie-Ardakani M-R, Hajiazim M, Raznahan M, Akhondzadeh S. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum Psychopharmacol. 2008;23(2):79-86.  https://doi.org/10.1002/hup.902
  10. Jungerman T, Rabinowitz D, Klein E. Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study. J Clin Psychopharmacol. 1999;19(6):522-525.  https://doi.org/10.1097/00004714-199912000-00006.
  11. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004;55(2):165-171.  https://doi.org/10.1016/s0006-3223(03)00707-8.
  12. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000;157(5):826-828.  https://doi.org/10.1176/appi.ajp.157.5.826
  13. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008;106(2-3):320-327.  https://doi.org/10.1016/j.schres.2008.08.012
  14. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56(1):21-27.  https://doi.org/10.1001/archpsyc.56.1.21
  15. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004;71(2-3):239-248.  https://doi.org/10.1016/j.schres.2004.03.013
  16. Tsai GE, Yang P, Chang Y-C, Chong M-Y. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006;59(3):230-234.  https://doi.org/10.1016/j.biopsych.2005.06.032.
  17. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593-1602. https://doi.org/10.1176/appi.ajp.2007.06081358
  18. Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PJ, Harvey PD, Loebel A, Watsky E, Siu CO, Romano S. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J Clin Psychopharmacol. 2010;30(4):425-430.  https://doi.org/10.1097/JCP.0b013e3181e69042
  19. Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, Gomez JC. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res. 2013;150(2-3):434-441.  https://doi.org/10.1016/j.schres.2013.08.020
  20. Marx CE, Keefe RSE, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, Shampine LJ. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2009;34(8):1885-1903. https://doi.org/10.1038/npp.2009.26
  21. Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, Weizman A, Lerner V. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010;71(10):1351-1362. https://doi.org/10.4088/JCP.09m05031yel
  22. Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev. 2012;1:CD007967. https://doi.org/10.1002/14651858.CD007967.pub2
  23. Conley RR, Boggs DL, Kelly DL, McMaho n RP, Dickinson D, Feldman S, Ball MP, Buchanan RW. The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia. Clin Neuropharmacol. 2009;32(2):69-74.  https://doi.org/10.1097/WNF.0B013E31816F2795
  24. Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi S-H, Rezazadeh S-A. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1810-1815. https://doi.org/10.1016/j.pnpbp.2008.08.001
  25. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(8):1040-1047. https://doi.org/10.1176/appi.ajp.2008.07071135.
  26. Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(6):968-975.  https://doi.org/10.1038/npp.2012.259
  27. Damulin IV, Zhivolupov SA, Zaitsev OS, Maksimova MYu, Markin SP, Samartsev IN, Sanadze AG, Strokov IA. Neuromidin in clinical practice. M: Medical information Agency LLC. 2nd ed., reprint. and add. 2016;60. (In Russ.).
  28. Kamchatnov PR, Dzugaeva FK, Chugunov AV, Kazakov AYu. Use of ipidacrine in patients with peripheral nervous system diseases. RMJ. 2018;12(I):44-48. (In Russ.).
  29. Chelapina MV, Sharova EV, Zaitsev OS. The Effects of ipidakrina (the»Neiromidin») in the parameters of the EEG in severe brain trauma. Uspehi sovremennogo estestvoznania. 2008;1:38-40. (In Russ.).
  30. Fedin AI, Solovyova EYu. Results of Russian multicentre observational study of Ipigrix effect on motor, sensory and cognitive functions in patients with peripheral and central nervous system diseases in conditions of actual clinical practice. Medicinskiy Alphavit. 2018;2(17):9-12. (In Russ.).
  31. Damulin IV, Stepkina DA, Lokshina AB. Use of neuromidin in mixed (vascular and Alzheimer’s) dementia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2011;111(2):40-43. (In Russ.).
  32. Morozova MA, Beniashvili AG, Rupchev GE, Lepilkina TA, Starostin DS, Brusov OS. Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(11):28-35. (In Russ.).
  33. Mashkovsky MD. Medicines. In 2 p. Manual for doctors: Handbook. M.: Meditsina;1993. (In Russ.).
  34. Burov IV, Robakidze TN, Kadysheva LV, Voronin AE., Shaposhnikova GI. Study of anti-amnesic activity of amiridin in a model of amnesic syndrome. Biull Eksp Biol Med. 1991;111(6):614-617. 
  35. Burov IV, Baimanov TD, Tat’ianenko LV, et al. Effects of amiridin and tacrine, drugs effective in Alzheimer’s disease, on the activity of monoamine oxidase A and B. Biull Eksp Biol Med. 1992;113(2):149-150. 
  36. Kojima J, Onodera K. Effects of NIK-247 and tacrine on muscarinic receptor subtypes in rats. Gen Pharmacol. 1998;30(4):537-541.  https://doi.org/10.1016/s0306-3623(97)00303-0
  37. Yoshida S, Suzuki N. Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. Eur J Pharmacol. 1993;250(1):117-124.  https://doi.org/10.1016/0014-2999(93)90628-u
  38. Onodera K, Kojima J, Wachi M. Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task. Nihon Shinkei Seishin Yakurigaku Zasshi. 1998;18(2):33-37. 
  39. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol. 2000;22(8):609-613.  https://doi.org/10.1358/mf.2000.22.8.701373
  40. Gavrilova SI, Koncevoy VA, Mikhailova NM. Comparative efficacy of amiridine treatment for Alzheimer’s type dementia and vascular dementia. Voprosy gerontopsikhiatrii. 1991;5:132-151. (In Russ.).
  41. Ivanova E, Khan A, Liharska L, et al. Validation of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-Ru) and Normative Data. Innov Clin Neurosci. 2018;15(9-10):32-48. 
  42. Keefe RSE, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins K. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res. 2008;102(1-3):108-115.  https://doi.org/10.1016/j.schres.2008.03.024
  43. Sarkisyan GR, Gurovich IYa, Keefe RS. Normative data for the russian population and standartization of «Brief Assessment of Cognition in Schizophrenia (BACS)». Sotsial’naya i Klinicheskaya Psikhiatriya. 2010;3:13-20 (In Russ.).
  44. Hall RC. Global assessment of functioning. A modified scale. Psychosomatics. 1995;36(3):267-275.  https://doi.org/10.1016/S0033-3182(95)71666-8
  45. Exner Jr JE. The Rorschach: A comprehensive system: Interpretation. Vol. 2. 2nd ed. New York: John Wiley & Sons; 1991.
  46. Assanovich MA. The integrative system of psychodiagnostics by the Rorschach method. M.: Kogito-Tsentr; 2011. (In Russ.).
  47. Rund BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull. 1998;24(3):425-435.  https://doi.org/0.1093/oxfordjournals.schbul.a033337
  48. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68(1):1-9.  https://doi.org/10.1016/S0920-9964(03)00097-5
  49. Strauss GP, Gold JM. A new perspective on anhedonia in schizophrenia. Am J Psychiatry. 2012;169(4):364-373.  https://doi.org/10.1176/appi.ajp.2011.11030447
  50. Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull. 2008;34(5):835-847.  https://doi.org/10.1093/schbul/sbn068
  51. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-485.  https://doi.org/10.1176/appi.ajp.2010.10060855
  52. Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013;150(1):58-63.  https://doi.org/10.1016/j.schres.2013.08.008
  53. Cella M, Swan S, Medin E, Reeder C, Wykes T. Metacognitive awareness of cognitive problems in schizophrenia: exploring the role of symptoms and self-esteem. Psychol Med. 2014;44(3):469-476.  https://doi.org/10.1017/S0033291713001189
  54. Cella M, Reeder C, Wykes T. It is all in the factors: effects of cognitive remediation on symptom dimensions. Schizophr Res. 2014;156(1):60-62.  https://doi.org/10.1016/j.schres.2014.03.032
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.